Bristol-Myers Squibb Co. (BMY)

66.53
NYSE : Health Technology
Prev Close 66.53
Day Low/High 0.00 / 0.00
52 Wk Low/High 51.56 / 70.05
Avg Volume 6.87M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 112.58B
EPS 0.60
P/E Ratio 110.41
Div & Yield 1.60 (2.28%)

Latest News

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Could Pfizer really buy Bristol-Myers Squibb? Despite the latter's $112 billion market cap, Citi analyst Andrew Baum lays out the case for why it makes sense.

Bristol-Myers 'Is Back' and Could Soar Another 14%

Bristol-Myers 'Is Back' and Could Soar Another 14%

Could Bristol-Myers Squibb stock really jump another 14% after rallying 12% so far in 2018? According to Morgan Stanley, the answer is 'yes.'

A Rally With Weak Breadth

The rebound continues but with weaker breadth than you might expect.

These Were the 3 Hottest Stories on Wall Street Thursday

These Were the 3 Hottest Stories on Wall Street Thursday

All three major indices gained more than 1% Thursday.

Jim's Daily Rundown

Jim discusses his Real Money article from this morning, Waste Management's earnings, and more!

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

You can buy it here or you can buy it higher.

SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Bristol-Myers Squibb Company

SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Bristol-Myers Squibb Company

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY) violated federal securities laws.

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains

Stocks finished higher on Wednesday.

Nektar Shares Surge on Bristol-Myers Collaboration

Nektar Shares Surge on Bristol-Myers Collaboration

Bristol-Myers will pay $1.85 billion up front plus up to $1.78 billion in potential milestone payments to Nektar, which was reported earlier this month to be mulling options including a sale.

Bristol-Myers Squibb And Nektar Therapeutics Announce Global Development & Commercialization Collaboration For Nektar's CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb And Nektar Therapeutics Announce Global Development & Commercialization Collaboration For Nektar's CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) announced today the companies have executed a global strategic development and commercialization collaboration for Nektar's lead...

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Bristol-Myers Squibb Company

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Bristol-Myers Squibb Company

Levi & Korsinsky announces it has commenced an investigation of Bristol-Myers Squibb Company (NYSE:BMY) concerning possible violations of federal securities laws.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Bristol-Myers Squibb Company

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Bristol-Myers Squibb Company

Levi & Korsinsky announces it has commenced an investigation of Bristol-Myers Squibb Company (NYSE:BMY) concerning possible violations of federal securities laws.

Cramer: Finding Winning Stocks Is Like Finding a Needle in a Haystack

Cramer: Finding Winning Stocks Is Like Finding a Needle in a Haystack

It is often better advice just to sit on your hands because we know from yesterday that any rally is suspect or ephemeral at best.

Bristol-Myers Squibb To Take Part In Leerink 7th Annual Global Healthcare Conference

Bristol-Myers Squibb To Take Part In Leerink 7th Annual Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in the Leerink Annual Global Healthcare Conference on Thursday, February 15, 2018, in New York.

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.

Dow Tumbles 1,175 Points, Largest Single-Day Point Loss Ever

Dow Tumbles 1,175 Points, Largest Single-Day Point Loss Ever

Stocks dive on Monday following a selloff that led Wall Street to its worst weekly performance in two years on Friday.

Bristol Myers Beats Estimates, Gives Positive News on Lung Cancer Drugs

Bristol Myers Beats Estimates, Gives Positive News on Lung Cancer Drugs

"We consider today's results as a breakthrough in cancer research," said Bristol-Myers chairman and CEO Giovanni Caforio of the CheckMate -227 study on an earnings call Monday.

Stock Selloff, Broadcom and Qualcomm, Super Bowl LII - 5 Things You Must Know

Stock Selloff, Broadcom and Qualcomm, Super Bowl LII - 5 Things You Must Know

Stock futures point to an ugly start for Wall Street on Monday, Broadcom set to raise its offer for Qualcomm, the Philadelphia Eagles beat the New England Patriots in Super Bowl LII.

Bristol-Myers Squibb Reports Fourth Quarter And Full Year Financial Results

Bristol-Myers Squibb Reports Fourth Quarter And Full Year Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2017, which were highlighted by strong sales for Opdivo and Eliquis along with regulatory and clinical...

Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) With The Opdivo Plus Yervoy Combination Versus Chemotherapy In First-Line Non-Small Cell Lung Cancer (NSCLC) Patients With High Tumor Mutation Burden (TMB)

Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) With The Opdivo Plus Yervoy Combination Versus Chemotherapy In First-Line Non-Small Cell Lung Cancer (NSCLC) Patients With High Tumor Mutation Burden (TMB)

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the ongoing Phase 3 CheckMate -227 study met its co-primary endpoint of progression-free survival (PFS) with the Opdivo (nivolumab) plus Yervoy...

The Easy Money in This Market Has Been Made

The Easy Money in This Market Has Been Made

The truth is, the environment has changed.

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.

Jim's Daily Rundown

In today's video, Jim discusses the government shutdown, an Eli Lilly downgrade, Schlumberger after Friday's earnings, and several other market-related topics.

European Commission Approves Bristol-Myers Squibb's Yervoy (ipilimumab) For Treatment Of Pediatric Patients 12 Years And Older With Unresectable Or Metastatic Melanoma

European Commission Approves Bristol-Myers Squibb's Yervoy (ipilimumab) For Treatment Of Pediatric Patients 12 Years And Older With Unresectable Or Metastatic Melanoma

Bristol-Myers Squibb Company (NYSE:BMY) announced today that the European Commission (EC) has expanded the indication of Yervoy (ipilimumab) to include treatment of advanced (unresectable or metastatic) melanoma in...

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Demonstrates Clinical Activity In Previously Treated Patients With DMMR Or MSI-H Metastatic Colorectal Cancer

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Demonstrates Clinical Activity In Previously Treated Patients With DMMR Or MSI-H Metastatic Colorectal Cancer

Bristol-Myers Squibb Company (NYSE:BMY) today announced new data from a cohort of the phase 2 CheckMate -142 trial evaluating Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of patients with DNA...

The Case For Buying Bristol-Myers Squibb

The Case For Buying Bristol-Myers Squibb

After a sideways consolidation, look to add to this drug maker.

TheStreet Quant Rating: B (Buy)